Introduction 1
The microenvironment - the sanctuary in which a tumor originates - plays a critical role in 2 tumor initiation and progression, and is created by the complex relationship between tumor cells 3 and their surrounding tissues consisting of extracellular matrices, extracellular molecules, and 4 host cells. [1] [2] [3] [4] [5] [6] [7] Knowledge of the complicated interplay within these niches however, is still limited. 5
In particular, the exact mechanism of how the host cells that comprise normal stroma are altered 6 during tumor progression and how they reciprocally influence tumor cells during tumorigenesis 7 is poorly understood. By addressing these fundamental issues, the development of therapeutic 8 strategies targeted at specific interactions occurring between the tumor and its microenvironment 9 is ultimately envisaged. 10
Given that the head and neck region is an environment challenged by a large variety of 11 insults, including pathogens, foods, and chemicals, the aforementioned relationship between 12 cancer cells and inflammatory stroma might be of particular importance for malignancies arising 13
there. Head and neck cancers, over 90% of which are squamous cell carcinomas (SCCs), 8 14 represent approximately 6% of all new cancers in the United States, 9 and consistently rank as one 15 of the top ten cancers worldwide. 10 More worrying is that the incidence of head and neck cancer 16 appears to be increasing in many parts of the world. [11] [12] [13] [14] Head and neck squamous cell carcinoma 17 (HNSCC) is characterized by a high degree of local invasiveness and a high rate of metastasis to 18 the cervical lymph nodes. 15 Survival of patients with HNSCC has not improved in the last 40 19 years, despite recent advances in surgical procedures and the availability of new 20 chemotherapeutic agents. In addition, surgical treatment results in significant functional and 21 cosmetic defects;; therefore, it is important to develop conservative therapeutics, whereupon 22 identification of markers for HNSCC aggressiveness would be worthwhile to decide the most 23 suitable treatment for each patient from therapeutic options. 16 
24
As with other cancers, most of the head and neck cancer deaths are accounted for by local 25 invasion and distant metastasis. The landmark of carcinoma progression during the invasive and 26 1 some modifications according to the manufacturer's protocol. Briefly, cells (2 × 10 4 ) were 2 resuspended in 0.5 ml complete DMEM containing 0.3% collagen (type I-A, Nitta Gelatin, 3
Osaka, Japan), and plated on a 12-well dish. After the collagen solution had gelled, 1 ml 4 complete DMEM was added to each well and changed every 7 days. Alternatively, the cells were 5 resuspended in 0.8 ml Matrigel (BD-Discovery Labware, Bedford, MA), and plated on a 24-well 6 dish. After the Matrigel had gelled, 0.5 ml complete DMEM was added to each well and changed 7 every 7 days. After 21 days, colonies were photographed. 8
Endothelial Cell Migration Assay 9
The chemotaxis assay was performed using 24-well Cell Culture Inserts with 8.0-10 (Nunc, Kamstrupvej, Denmark), as described previously. 28 Conditioned media obtained were 11 added as a chemoattractant into the lower chamber, and HUVECs (1.5 × 10 4 ) were seeded in the 12 upper chamber. In some experiments, OPG (100 ng/ml) or an anti-VEGF antibody (1 13 added to the media. Recombinant human VEGF (10 ng/ml) was also used as a control. After 24 h 14 incubation at 37°C, transferred HUVECs to the lower surface of filters were fixed and stained by 15 0.2% crystal violet, and the cell number in randomly selected fields was counted. Levels of 16 secreted VEGF in conditioned media were analyzed by enzyme-linked immunosorbent assay 17 (ELISA) according to the manufacturer 's recommendation. 18 
Statistical Analysis 19
All data, unless otherwise specified, are expressed as the mean ± standard deviation (S.D.), 20 subjected to one-way analysis of variance, followed by comparison using a Student's t-test, a 21
Mann-Whitney U test, or a Spearman's test to evaluate the difference between the samples. A P 22 value less than 0.05 was considered significant in each test, is represented by an asterisk over the 23 error bars in the figures, and is described in the figure legends.
To explore the possible implication of RANKL in HNSCC progression, we first examined the 3 expression of RANKL mRNA by quantitative RT-PCR in 20 human HNSCC samples, including 4 those in the tongue and the gingiva. In all cases, high expression (from 6 to 123-fold) is observed 5 compared to human gingival fibroblast, HGF ( Figure  1A) . Next, to clarify the relationship 6 between RANKL expression and HNSCC progression, HNSCC samples were categorized into 7 various groups that are based on difference in clinical staging or histological differentiation, and 8 RANKL expression levels were compared across the groups using non-parametric analyses. The 9 expression level of RANKL was positively correlated with the histological grade of 10 differentiation ( Figure  1B ), but not with tumor-node-metastasis (TNM) staging (rank correlation 11 coefficient: = 0.0264, P = 0.497). Because factors related to TNM can be affected by the phase 12 when the patients are diagnosed, this result does not rule out the possibility that RANKL is 13 implicated in progression and biological malignancies of HNSCC. Indeed, when we utilized the 14 Yamamoto-Kohama classification, a criterion based on histological architecture and mode of 15 invasion, 29 strikingly high expression was observed in a YK-4 group (diffuse invasive type;; 16 Figure  1C ). 17
When cases were available for histological examination (n = 16), immunohistochemical 18 analysis was also performed to further evaluate the role of the RANKL protein in HNSCC 19 malignancy, and revealed that poorly differentiated SCC (YK4), in which atypical cancer cells 20 diffusely invaded into surrounding tissues, expressed abundant RANKL proteins ( Figure  1D , left 21 panels). Meanwhile, the level was low in well-differentiated SCC (YK-3), in which tumor cells 22 showed expanded growth with obvious keratinization ( Figure  1D , right panels). Statistical 23 analyses also elucidated that RANKL expression was correlated with the histological grade of 24 differentiation and mode of invasion (Figure  1 , E and F). Thus, the expression level of RANKL 25 is intimately associated with the grade of histological differentiation of HNSCC. Nevertheless, toour surprise, none of the tested HNSCC cell lines, namely, HSC-2-4, SAS, and Ca9-22, 1 displayed such abundant RANKL expression as that observed in vivo, albeit the expression in 2 these cell lines, except for HSC-2, is higher than that in HGF (~3.2-fold) (see also Figure  1A ). In 3 particular, although the HSC-2, HSC-3, and SAS cell lines are established from moderately to 4 poorly differentiated SCC with aggressive invasiveness, and in fact displayed similar 5 characteristics when the cells were inoculated into mice oral tissue (see below), the RANKL 6 expression level in these cell lines might be repressed under culture conditions. 7
Environment-Dependent Expression of RANKL 8
We thus hypothesized that repressed RANKL expression under culture conditions is due to a lack 9 of environmental cues that are required for the maintenance of its expression. To test this 10 possibility, HSC-3 cells were inoculated into the masseter muscles of mice (one of the most 11 established sites for a head and neck cancer orthotopic model), [31] [32] [33] and the amount of RANKL 12 mRNA was analyzed by RT-PCR using a primer set specific for human RANKL. As expected, 13 RANKL expression in all tumor tissues tested (n = 3) was dramatically augmented (Figure  2A To assess the contribution of the oral environment to RANKL expression and subsequent 2 tumor formation, HSC-3 cells were also injected into the muscle of hindlimbs, which was 3 selected in analogy to the orthotopic site (intramuscular) and by the distance from the head and 4 neck region. As shown in Figure  2 , E and F, tumors formed in the hindlimbs (H) were 5 significantly smaller than those in the masseter region (M). In parallel with tumor weight, 6 RANKL could be detected in the masseter region tumors ( Figure  2G ;; M1 and M2), but not in the 7 hindlimb ones ( Figure  2G ;; H1 and H2) at both mRNA and protein levels. Essentially similar 8 results were obtained when HSC-2 and SAS cells were used (data not shown). Thus, RANKL 9 expression requires the orthotopic environment and correlates with tumor formation ability. 10
RANKL Expression Accelerates Tumor Formation 11
Because none of the HNSCC cell lines expressed RANKL plentifully, compared to the in vivo 12 condition, we established HNSCC cell lines that stably express RANKL, in order to further 13 confirm the role for RANKL in HNSCC tumor formation. Of the cell lines that were able to form 14 tumors in the masseter region (see Figure  2) , we utilized HSC-3 cells, which display poorly 15 differentiated, invasive SCC uniformly without apparent necrosis (see Figure  2C 
RANKL Induced Malignant Phenotypes in an In Vivo-Specific Manner 21
To test whether RANKL-expressing tumors in fact underwent EMT, we evaluated the expression 22 levels of E-cadherin, N-cadherin, and several transcription factors implicated in EMT. 21 However, 23
we could note no differences in their expression in vitro (data not shown). Moreover, 24 notwithstanding the dramatic increment in tumor formation of RANKL-expressing cells in the 25 hindlimbs, in vitro proliferation of R2 cells was substantially slower than that of C1 cells ( Figure5A ). In addition, there is no significant difference in in vitro motility ( Figure 5B marginally upregulated compared to that toward control DMEM. In contrast, conditioned 6 medium of R2 cells substantially facilitated HUVEC migration, which was reverted in the 7 presence of osteoprotegerin (OPG), a RANKL decoy receptor that inhibits RANK-RANKL 8 signaling ( Figure  7D ). It is noteworthy that an equivalent level of vascular endothelial growth 9 factor (VEGF) was secreted in media of both C1 and R2 cells ( Figure  7E ). In addition, 10 expression levels of human and murine VEGF were not altered, regardless of RANKL 11 expression and whether cell growth conditions were in vivo or in vitro, as measured by RT-PCR 12 using primers specific for respective species ( Figure  7F) . Moreover, the HNSCC- or RANKL-13 dependent HUVEC migration could not be hampered by an anti-VEGF antibody, which at a 14 same concentration almost completely inhibited the migration induced by VEGF ( Figure  7G ) 15 These results together demonstrate that expressed RANKL promotes tumor angiogenesis in a 16 manner independent of VEGF. 17
Discussion 18
In the present study, we disclose that RANKL expression is specifically detected in the intravital 19 environment, which in turn promotes EMT, tumorigenesis, and angiogenesis of HNSCCs in vivo. 20
These observations highlight RANKL as a "bio-functional" marker molecule that should be 21 useful for both diagnosis and therapy of this disease. 22
One of the most serious clinical concerns accompanying HNSCC is a high potential for local 23 invasion, frequently targeting the adjacent bone, thus requiring radical surgical procedures that 24 put much strain on patients due to the deprivation of fundamental functions, includingrecognition of RANKL and its relevant signaling as potential targets for conservative therapy 1 may enable us to hamper tumorigenesis and invasion by cutting the connection between HNSCC 2 and the tumor microenvironment. In addition to the conventional molecular targeted therapy (i.
41-43 However, in the case that 6 these molecules are not essential for cancer cell survival, the cells can escape the challenge of the 7 immune system by reducing the expression of the antigens. Since the expression of RANKL in 8 response to the microenvironment is critical for HNSCC progression (Figures  2  and  4) , it is 9 definitively a possibility that RANKL-RANK signaling might be central to the conservative, 10 multimodal treatment for this disease. The mechanism by which RANKL is expressed in a manner specific to the 24 microenvironment remains to be addressed. Given the specific character of the head and neck asplay an indispensable role in HNSCC tumor initiation and progression. [56] [57] [58] [59] [60] In fact, genome-wide 1 microarray analyses demonstrate the upregulation of inflammation-associated molecules in this 2 cancer.
61, 62
The head and neck region including the oral cavity is also known as a site abundant in 3 a range of growth factors, which are known to contribute to malignant conversion of HNSCC 4 through activating diverse cancer-related signaling pathways.
23, 54, 55, 63 We thus extended the 5 investigation of RANKL-inducing agents from factors directly implicated in HNSCC 6 malignancy (EGF or PTHrP) to those implicated in EMT (such as TGF-7 inflammatory cytokines (data not shown), but failed to identify it. Because the morphological 8 differences between control and RANKL-expressing cells were observed in colonies formed in a 9 collagen gel and Matrigel ( Figure  6F ), we thought that the engagement with extracellular 10 matrices is likely to attribute to RANKL induction. Unfortunately, however, no extracellular 11 matrices per se could evoke RANKL expression in vitro (data not shown). Therefore, we infer 12 that the efficient RANKL expression and the subsequent EMT promotion and tumor intimate association between NF-22 RANK, and cell adhesion has been described, [64] [65] [66] [67] and recently, integrin has been shown to play a 23 role in escaping anoikis. 68 Research addressing this issue should be continued. In either case, we 24 can state that RANKL is an in vivo-specific functional marker for HNSCC malignancy.expressed RANKL plays a hitherto unidentified role in tumor progression, namely inducing 1 EMT and angiogenesis. It may be noteworthy that aggressiveness of angiogenesis in HNSCC 2 was correlated with RANKL expression level, but not the VEGF level, suggesting that VEGF-3 independent strategies should be taken into consideration to hamper angiogenesis in HNSCC. 4
The function of RANKL as an EMT inducer was also specific for in vivo conditions. In the future, 5
we believe that through our observations and the unveiling of remaining associated issues, the 6 establishment of more rational, potent anti-cancer therapy with consideration of the 7 communication between cancer cells and their respective microenvironment will eventually be 8 accomplished. 
